Dark Horse Consulting Group Inc.
Anthony Davies has a diverse range of experience in the biotech industry. Starting in 2002, they worked as an Associate Director of Process Development at Syrrx. From 2004 to 2005, they served as Senior Director of Manufacturing at ZymeQuest. Davies then became Director of Process Development at Serologicals in 2005. Anthony later joined Geron Corporation as VP of Product Development from 2006 to 2012. In 2013, they were Chief Technology Officer at Capricor, Inc., responsible for manufacturing, quality systems, and development of their cell-based therapeutic portfolio. From 2012 to 2015, Davies was a Scientific Advisory Board Member at Park BioVentures LLC. In 2014, they became a member of the Scientific Advisory Board at BioLife Solutions, Inc. The following year, in 2017, they became a Non-Executive Director at TrakCel Ltd. Anthony later founded their own consultancy, Dark Horse Consulting Group Inc., which specializes in cell and gene therapy, mergers and acquisitions, and engaging strategic corporate partners and investors. Currently, they are also a Mentor for the Advanced Therapies Stream at Creative Destruction Lab, a nonprofit organization that supports the growth of science and technology-based companies.
Anthony Davies completed their education with a PhD in Biochemical Engineering from the University of Birmingham, which they pursued from 1986 to 1990. Prior to this, they obtained an MA degree in Natural Sciences with a specialization in Biochemistry from the University of Cambridge between 1983 and 1986. Anthony's earlier education included attending Brighton College from 1972 to 1982. The specific degree obtained and field of study during this time period is not mentioned.
This person is not in any offices
Dark Horse Consulting Group Inc.
AT DARK HORSE CONSULTING, we work to accelerate cell and gene therapies through our unmatched expertise. Our consulting team has extensive CGT industry experience with knowledge spanning manufacturing, process development, comparability, analytical dev, quant modeling, quality systems, regulatory support, preclinical dev, device dev, program management, facility design and enginnering, market research, and due diligence and business strategy. Many of our consultants also bring experience from adjacent, more mature, sectors, including traditional biologics, small molecules, medical devices, and management consulting. Client requests range from scientific expertise to tactical needs to strategic considerations to business development. We understand the unique challenges faced by Cell and Gene Therapy developers like none other. We apply best practices from across this and other industries to address the needs of our clients, who range from biopharmaceutical companies to tools & tech providers to investment firms.